This Article Abstract Full Text (PDF) Data Supplement Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kataoka, H. Articles by Kita, T. Search for Related Content PubMed PubMed Citation Articles by Kataoka, H. Articles by Kita, T. Pubmed/NCBI databases Substance via MeSH Related Collections Apoptosis Acute coronary syndromes Lipid and lipoprotein metabolism Oxidant stress

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:955.)
© 2001 American Heart Association, Inc.

Vascular Biology

Oxidized LDL Modulates Bax/Bcl-2 Through the Lectinlike Ox-LDL Receptor-1 in Vascular Smooth Muscle Cells

Hiroharu Kataoka; Noriaki Kume; Susumu Miyamoto; Manabu Minami; Masafumi Morimoto; Kazutaka Hayashida; Nobuo Hashimoto; Toru Kita

From the Departments of Geriatric Medicine (N.K., M. Minami, K.H., T.K.) and Neurosurgery (H.K., S.M., M. Morimoto, N.H.), Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Correspondence to Noriaki Kume, MD, PhD, Department of Geriatric Medicine, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. E-mail nkume{at}5fkuhp.kyoto-u.ac.jp

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—Oxidized low density lipoprotein (Ox-LDL) induces apoptosis in vascular smooth muscle cells (VSMCs), which may increase atherosclerotic plaque instability. In this study, we examined the molecular mechanisms causing the Ox-LDL–induced apoptosis in VSMCs, especially focusing on the involvement of Bax/Bcl-2 and the lectinlike Ox-LDL receptor-1 (LOX-1). In cultured bovine aortic smooth muscle cells (BASMCs), Ox-LDL at high concentrations (>60 µg/mL) induced cell death as demonstrated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. DNA fragmentation was increased in BASMCs treated with high concentrations of Ox-LDL, indicating that the Ox-LDL–induced cell death in VSMCs was apoptosis. Ox-LDL upregulated LOX-1 expression through phosphorylation of extracellular signal–regulated kinase in BASMCs, and a neutralizing anti–LOX-1 monoclonal antibody, which can block LOX-1–mediated cellular uptake of Ox-LDL, prevented the Ox-LDL–induced apoptosis in BASMCs. This antibody also suppressed the increase in the Bax to Bcl-2 ratio induced by Ox-LDL in BASMCs. Furthermore, LOX-1 expression was well colocalized with Bax expression in the rupture-prone shoulder areas of human atherosclerotic plaques in vivo. LOX-1 may play an important role in Ox-LDL–induced apoptosis in VSMCs by modulating the Bax to Bcl-2 ratio. These molecular mechanisms may be involved in destabilization and rupture of atherosclerotic plaques.

Key Words: atherosclerosis • lipoproteins • receptors • apoptosis

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Several lines of evidence have suggested that oxidized LDL (Ox-LDL) may play crucial roles in the pathogenesis of atherosclerosis and destabilization of the atherosclerotic plaque.¹ Ox-LDL can bind to scavenger receptors and subsequently be internalized by macrophages, resulting in foam cell formation.² Ox-LDL and its lipid constituents can be major factors that cause endothelial dysfunction by transcriptionally inducing proatherogenic genes.^{3 4 5} In addition to its role in foam cell transformation of macrophages and endothelial dysfunction, Ox-LDL is known to induce apoptosis of vascular smooth muscle cells (VSMCs).^{6 7} Because areas of the fibrous cap in vulnerable plaques are typically thin and contain fewer VSMCs, the Ox-LDL–induced apoptosis in intimal VSMCs may increase plaque instability, leading to plaque rupture in acute coronary syndromes. However, the molecular mechanisms involved in Ox-LDL–induced apoptosis in VSMCs remain to be elucidated.

The lectinlike Ox-LDL receptor-1 (LOX-1) is a receptor for Ox-LDL that was initially cloned from cultured vascular endothelial cells.⁸ LOX-1 can support binding, internalization, and degradation of Ox-LDL.⁹ Subsequent studies have revealed that LOX-1 is also expressed by VSMCs in vitro^{10 11} and in vivo,¹² suggesting that LOX-1 may be involved in some of the functional modulations caused by Ox-LDL in VSMCs.

In contrast to necrosis, apoptosis is regulated by various apoptosis-related proteins. Bcl-2 acts as an anti-death factor, preventing the release of cytochrome c and other apoptogenic factors from mitochondria.¹³ In contrast, Bax reduces mitochondrial membrane potential and thereby causes cytochrome c release and caspase activation, which leads to apoptosis.¹⁴ Bcl-2¹⁵ and Bax¹⁶ are expressed in human atheromas, suggesting that these factors may in fact regulate apoptotic cell death in atherosclerotic plaques.

Therefore, in the current study, we examined whether Bax/Bcl-2 can be modulated by Ox-LDL and whether LOX-1 is involved in this process in VSMCs by use of a neutralizing anti–LOX-1 monoclonal antibody. Here we provide evidence for the first time that LOX-1 mediates, at least in part, the Ox-LDL–induced Bax/Bcl-2 modulation and apoptosis in VSMCs.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Cells and Reagents
Bovine aortic smooth muscle cells (BASMCs) were isolated and cultured as previously described.¹⁰ Cells used for experiments were between passage levels 2 and 5. Isolation of human LDL, oxidative modification of LDL with cupric ion, and labeling of LDL with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (Molecular Probes) were performed as previously described.¹⁷ Values for thiobarbituric acid–reactive substances in Ox-LDL and native LDL were 9.86±1.32 and 1.15±0.21 nmol malondialdehyde per milligram protein, respectively. Anti–LOX-1 monoclonal antibodies (5-144¹⁸ and 2-32¹² ) were prepared as previously described. Monoclonal antibodies for Bax (B-9) and Bcl-2 (C-2) were purchased from Santa Cruz. The mitogen-activated protein kinase (MAPK) inhibitors SB203580 and PD098059 were obtained from Calbiochem.

Measurements of Cytotoxicity
Mitochondrial dehydrogenase activity was used as an index of cell viability and was assessed with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.¹⁹ BASMCs seeded onto 96-well plates at 10⁴ cells per well were incubated in Dulbecco’s modified Eagle’s medium/1% fetal calf serum with various reagents for the indicated times. Then MTT (final concentration, 0.5 mg/mL; Roche) was added to each well, and the wells were incubated at 37°C under 5% CO₂ for 4 hours. Cells were lysed in 10% (wt/vol) SDS in 0.01 mol/L HCl before absorbance was measured at 595 nm. Data are expressed as mean±SD of quadruplicate wells.

Determination of DNA Fragmentation
DNA fragmentation was visualized in situ on fixed cells by using the terminal deoxynucleotidyl transferase–mediated dUTP-biotin nick end labeling (TUNEL) procedure by Gavrielli et al²⁰ by use of an in situ cell death detection kit (Roche), followed by nuclear staining with 500 ng/mL of 4',6-diamidino-2-phenylindole (DAPI) for 10 minutes at room temperature. DNA fragmentation was also quantified by using a cellular DNA fragmentation ELISA kit (Roche) as previously described.²¹ Data are expressed as mean±SD of quadruplicate wells.

Western Blot Analysis
After BASMCs were treated with various reagents in Dulbecco’s modified Eagle’s medium/1% fetal calf serum for the indicated times, Western blot analyses for detection of LOX-1, Bax, and Bcl-2 were performed as previously described.¹⁷

Immunohistochemistry
A total of 21 human carotid endarterectomy specimens were prepared as previously described.¹² After fixation with cold acetone and blocking, frozen sections were first incubated with an anti–LOX-1 monoclonal antibody (2-32), which was followed by incubation with a fluorescence dye, Alexa 488–conjugated secondary antibody for rat IgG (Molecular Probes). They were subsequently incubated with an anti-Bax monoclonal antibody, which was followed by incubation with a carbocyanine 3 (Cy3)-labeled anti-mouse IgG antibody (Chemicon International, Inc). Sections were observed under the fluorescence microscope.

Statistical Analysis
Statistical significance in the difference between 2 groups was determined by unpaired Student’s t test. ANOVA was used for comparisons among multiple groups. Statistical significance was established at P<0.01.

	Results

Top Abstract Introduction Methods Results Discussion References

 
High Concentrations of Ox-LDL Induce Apoptosis in BASMCs
To examine the effect of fully Ox-LDL on the viability of BASMCs, they were treated with various concentrations of Ox-LDL or native LDL and then subjected to the MTT assay. As shown in Figure 1A, Ox-LDL at high concentrations (>60 µg/mL) induced cell death, although it caused cellular proliferation at low concentrations (10 to 20 µg/mL). In contrast, native LDL did not affect cell viability. To determine whether the Ox-LDL–induced cell death in VSMCs was apoptosis or necrosis, DNA fragmentation was examined by a DNA fragmentation ELISA and TUNEL staining. Ox-LDL increased cellular DNA fragmentation in a dose-dependent manner in BASMCs (Figure 1B). Ox-LDL also increased the number of TUNEL-positive cells in BASMCs (Figure 1C). In contrast, native LDL did not have any effect on DNA fragmentation in BASMCs. These data indicate that Ox-LDL at high concentrations induces apoptosis in BASMCs.

View larger version (22K): [in this window] [in a new window]   Figure 1. Effects of Ox-LDL and native LDL on cell viability and DNA fragmentation in BASMCs. (A) BASMCs were treated with various concentrations of Ox-LDL (open circles) or native LDL (filled circles) for 24 hours. Cell viability was assessed by MTT assay. (B) Cellular DNA fragmentation was determined by ELISA. Results are expressed as percent of initial level. Values are mean±SD of quadruplicate wells. (C) BASMCs were treated with 60 µg/mL Ox-LDL (center) or native LDL (right) for 24 hours. Treatment with medium alone served as a control (left). Upper panels show DNA fragments labeled in situ by TUNEL procedure. Lower panels show nuclear staining by DAPI of the same field of view as the upper panels. Representative data of 3 independent experiments are shown.

Ox-LDL Upregulates LOX-1 Expression in BASMCs Through Phosphorylation of ERK
To explore the expression of LOX-1 in BASMCs, we performed Western blot analysis in both untreated and Ox-LDL–treated BASMCs. Although expression levels of LOX-1 protein were very low under basal condition in BASMCs, they were markedly upregulated by 40 to 80 µg/mL Ox-LDL, but not by native LDL (Figure IA; please see http://atvb.ahajournals.org.). Expression of LOX-1 protein was increased in a dose-dependent manner and peaked at 60 µg/mL Ox-LDL.

Ox-LDL has been known to activate MAPK in VSMCs.^{22 23} To explore whether the MAPK kinase (MEK)–extracellular signal-regulated kinase (ERK) pathway was involved in Ox-LDL–induced LOX-1 expression, the effects of PD98059, a specific inhibitor of MEK1, were examined. As shown in Figure IB (please see http://atvb.ahajournal org.), PD98059, but not the p38 MAPK inhibitor SB202190, dose-dependently inhibited Ox-LDL–induced LOX-1 expression. These results thus indicate that MEK-ERK, but not p38 MAPK, is involved in the Ox-LDL–induced expression of LOX-1 in BASMCs.

Ox-LDL–Induced Upregulation of LOX-1 Protein Is Followed by Ox-LDL–Induced Apoptosis in BASMCs
To examine whether LOX-1 is involved in Ox-LDL–induced apoptosis, time-course experiments were carried out in BASMCs. LOX-1 protein levels were increased as early as 4 hours and were sustained for 24 hours (Figure 2A). In contrast, Ox-LDL–induced cell death was detectable after 8 hours and became statistically significant after 12 hours in BASMCs (Figure 2B). These data indicate that the Ox-LDL–induced upregulation of LOX-1 precedes apoptotic cell death in BASMCs.

View larger version (37K): [in this window] [in a new window]   Figure 2. Time course of LOX-1 protein expression (A) and cell death (B) induced by Ox-LDL in BASMCs. BASMCs were incubated with Ox-LDL (60 µg/mL) for the indicated times. Levels of LOX-1 protein were measured by Western blot analysis (A). Cell viability was evaluated by MTT assay (B). A representative figure from 2 independent experiments is shown.

A Neutralizing Anti–LOX-1 Antibody Prevents Ox-LDL–Induced Apoptosis in BASMCs
To determine whether LOX-1 was involved in the Ox-LDL–induced apoptosis in VSMCs, BASMCs were incubated with 60 µg/mL Ox-LDL in the presence or absence of a neutralizing anti–LOX-1 antibody (5-144) Before use of this antibody for experiments, we confirmed its ability to block the cellular uptake of Ox-LDL in Chinese hamster ovary cells stably expressing bovine LOX-1 (data not shown). In the MTT assay, this neutralizing antibody for LOX-1 dramatically reduced Ox-LDL–induced cell death in BASMCs (Figure 3A). DNA fragmentation induced by Ox-LDL was significantly decreased by incubation with this neutralizing antibody for LOX-1 (Figures 3B and 3C). In contrast, an isotype-matched control IgG did not show any significant effects on either cell viability or DNA fragmentation in Ox-LDL–treated BASMCs. This neutralizing antibody did not block either cell death (Figure 3A) or DNA fragmentation (Figure 3B) induced by tumor necrosis factor-, suggesting the specificity of LOX-1 for the Ox-LDL–induced apoptosis. These data indicate that LOX-1 mediates the Ox-LDL–induced apoptosis in BASMCs.

View larger version (19K): [in this window] [in a new window]   Figure 3. Effects of the anti–LOX-1 neutralizing antibody on Ox-LDL–induced apoptosis in BASMCs. (A) BASMCs were treated with Ox-LDL (60 µg/mL) or tumor necrosis factor- (TNF-; 500 IU/mL) in combination with 300 µg/mL anti–LOX-1 monoclonal antibody (5-144) or an isotype-matched control IgG for 24 hours. Cell viability was assessed by MTT assay. (B) Cellular DNA fragmentation was determined by ELISA. Results are expressed as percent of initial level. Values are mean±SD of quadruplicate wells. (C) BASMCs were treated with Ox-LDL (60 µg/mL) in the presence or absence (right) of 300 µg/mL anti–LOX-1 monoclonal antibody (5-144) (center) or isotype-matched control IgG (left) for 24 hours. Upper panels show DNA fragments labeled in situ by TUNEL procedure. Lower panels show nuclear staining by DAPI of the same field of view. Representative data of 3 independent experiments are shown.

A Neutralizing Antibody for LOX-1 Inhibits Ox-LDL–Induced Modulation of Bax and Bcl-2 Expression in BASMCs
In BASMCs, Ox-LDL increased Bax expression and decreased Bcl-2 expression in a dose-dependent manner (data not shown). To test whether LOX-1 mediated this increase in the Bax to Bcl-2 ratio in BASMCs, immunoblot analyses for Bcl-2 and Bax were performed in the presence of the anti–LOX-1 neutralizing antibody or an isotype-matched control IgG. The neutralizing antibody for LOX-1 inhibited the increase in the Bax to Bcl-2 ratio induced by Ox-LDL in BASMCs, suggesting that the LOX-1–mediated binding or uptake of Ox-LDL may increase the Bax to Bcl-2 ratio (Figure 4). Control IgG did not significantly affect the altered expression level of either Bax or Bcl-2 elicited by Ox-LDL.

View larger version (65K): [in this window] [in a new window]   Figure 4. Effects of the anti–LOX-1 neutralizing antibody on the Ox-LDL–induced increase in the Bax to Bcl-2 ratio in BASMCs. Confluent BASMCs were treated with 80 µg/mL Ox-LDL in the presence or absence of 300 µg/mL of an anti–LOX-1 neutralizing antibody (5-144) or an isotype-matched control IgG for 12 hours, and Western blot analyses were performed to evaluate the amounts of Bax (A) or Bcl-2 (B) protein. A representative figure from 3 independent experiments is shown.

LOX-1 Was Coexpressed With Bax in Human Atherosclerotic Plaques
To examine whether the LOX-1–mediated binding or uptake of Ox-LDL regulated Bax expression in vivo, double-label immunohistochemistry for LOX-1 and Bax was performed on human carotid endarterectomy specimens. As shown in Figure 5, LOX-1 was well colocalized with Bax in both the fibrous cap and shoulder regions of human atherosclerotic plaques. The expression of LOX-1 and Bax was more abundant in the shoulder regions than in the fibrous cap regions. These data suggest that Bax expression may be upregulated through a LOX-1–mediated pathway in vivo as well as in vitro.

View larger version (15K): [in this window] [in a new window]   Figure 5. Colocalization of LOX-1 and Bax by double-label immunohistostaining in 2 different sections (A through C, shoulder region; D through F, a fibrous cap) from human carotid endarterectomy specimens. LOX-1 expression was visualized by Alexa and appeared green (A, D), whereas Bax expression was marked with Cy3 and appeared red (B, E). Two images of the same field of view were superimposed (C and F).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Apoptosis of VSMCs may play important roles in the destabilization of atherosclerotic plaques. The present study has established that LOX-1 mediates the Ox-LDL–induced apoptosis in VSMCs through a Bax/Bcl-2–dependent pathway. Nishio and Watanabe²⁴ revealed that the Ox-LDL–induced apoptosis of VSMCs involved downregulation of Bcl-2 protein and activation of caspase 3. We have further demonstrated in this study that Ox-LDL upregulates Bax expression in VSMCs and that both the increase in Bax and the decrease in Bcl-2 were dependent on LOX-1–mediated Ox-LDL uptake or binding. The ratio of Bax to Bcl-2 appears to determine the susceptibility of cell death after application of apoptotic stimuli in various cell types.²⁵ Recent studies have revealed that VSMCs in human atherosclerotic lesions express Bax, which increases the susceptibility of these cells to undergo apoptosis.¹⁶ Taken together with our immunohistochemistry data (Figure 5) showing the colocalization of LOX-1 and Bax in human atherosclerotic plaques, LOX-1 may mediate the Ox-LDL–induced apoptosis in VSMCs through the increase in the Bax to Bcl-2 ratio in vivo.

Ox-LDL can also induce cell proliferation in VSMCs at low concentrations,^{26 27} which was confirmed by our data for the MTT assay (Figure 1A). Ox-LDL–induced proliferation of VSMCs may not depend on LOX-1 because LOX-1 expression levels were low at low concentrations of Ox-LDL. High concentrations of Ox-LDL were required to induce high levels of LOX-1 expression and apoptosis in VSMCs, thus supporting the conclusion that Ox-LDL–induced apoptosis of VSMCs is LOX-1 dependent.

LOX-1 is a receptor for Ox-LDL expressed in vascular endothelial cells,^{17 28} macrophages,^{29 30} and VSMCs^{10 11} in vitro and in vivo.^{12 31} These results suggest that LOX-1 may mediate some of the pathophysiological consequences induced by Ox-LDL in various cell types. In endothelial cells, LOX-1 is known to mediate upregulated expression of monocyte chemoattractant protein-1,³² apoptotic cell death,³³ and activation of nuclear factor-B.³⁴ However, the consequences of Ox-LDL binding or uptake through LOX-1 in VSMCs remain to be clarified. In this study, we demonstrated for the first time the functional alterations of VSMCs caused by Ox-LDL/LOX-1 interactions, which may play important roles in plaque rupture.

During atherogenesis, medial VSMCs dedifferentiate, proliferate, and transmigrate into the intima, resulting in the formation of fibrous caps together with extracellular matrixes.¹ VSMCs produce the extracellular matrixes, which can be degraded by metalloproteinases that are produced mainly by macrophages.³⁵ Ox-LDL has been known to promote plaque instability by regulating the expression of metalloproteinases in macrophages.^{36 37} In addition, Ox-LDL is likely to destabilize plaques by inducing apoptosis in intimal VSMCs. As demonstrated in this study, LOX-1 may be a key molecule in mediating the Ox-LDL–induced apoptosis in VSMCs leading to plaque rupture. Because LOX-1 expression in VSMCs can be upregulated by cytokines,¹⁰ lysophosphatidylcholine,¹¹ and Ox-LDL (please see online Figure IA), inflammatory responses in atheromas may enhance plaque vulnerability by inducing LOX-1 expression in intimal VSMCs. Our data from the double immunohistochemistry study showed that LOX-1 and Bax were colocalized, especially in the rupture-prone shoulder regions, thus supporting the notion that increased LOX-1 expression by inflammatory stimuli mediates the modulation of Bax and apoptosis in VSMCs, leading to plaque rupture. Moreover, we have recently identified soluble forms of LOX-1 that are proteolytically cleaved from the cell surface.³⁸ Serum levels of soluble LOX-1 may reflect the cellular expression levels of LOX-1 and thus, can be a predictor of acute coronary syndromes.

In conclusion, the present study has revealed 1 of the molecular mechanisms involved in the Ox-LDL–induced apoptosis in VSMCs. LOX-1 mediates the Ox-LDL–induced apoptosis in VSMCs, at least in part, through an increase in the Bax to Bcl-2 ratio. To our knowledge, this is the first evidence that demonstrates a functional consequence mediated by LOX-1 in VSMCs. Ox-LDL upregulates LOX-1 expression, which in turn may amplify the Ox-LDL–induced apoptosis in intimal VSMCs and thus finally elicit plaque rupture in coronary heart disease. Further studies related to the molecular mechanisms linking the Ox-LDL/LOX-1 interaction to the altered expression of Bax and Bcl-2 may provide new insights into the pathogenesis of atherosclerosis and plaque rupture.

	Acknowledgments

 
This work has been supported in part by a Center of Excellence grant (No. 12CE2006) and grants-in-aid (Nos. 11838008, 11694266, 11307018, and 32644) from the Minister of Education, Science and Culture of Japan and by the Japan Heart Foundation/Pfizer Grant for Research on Hypertension and Vascular Metabolism. We thank Japan Tobacco Inc, Pharmaceutical Frontier Research Laboratories, for producing and providing the monoclonal antibody 5-144. We thank the Kyoto Red Cross Blood Center for gifts of unused human plasma. We thank Dr Yoshinori Akiyama and Dr Izumi Nagata (Department of Neurosurgery, National Cardiovascular Center) for their generous gift of human carotid endarterectomy specimens. We also would like to acknowledge Kumiko Kanai and Akemi Saitoh for their excellent assistance in conducting the experiments.

Received November 7, 2000; accepted February 13, 2001.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138:S419–S420.[Medline] [Order article via Infotrieve]

2. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785–1792.

3. Kume N, Cybulsky MI, Gimbrone MA Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest. 1992;90:1138–1144.

4. Kume N, Gimbrone MA Jr. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest. 1994;93:907–911.

5. Zembowicz A, Jones SL, Wu KK. Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine. J Clin Invest. 1995;96:1688–1692.

6. Siow RC, Richards JP, Pedley KC, Leake DS, Mann GE. Vitamin C protects human vascular smooth muscle cells against apoptosis induced by moderately oxidized LDL containing high levels of lipid hydroperoxides. Arterioscler Thromb Vasc Biol. 1999;19:2387–2394.[Abstract/Free Full Text]

7. Thorne SA, Abbot SE, Winyard PG, Blake DR, Mills PG. Extent of oxidative modification of low density lipoprotein determines the degree of cytotoxicity to human coronary artery cells. Heart. 1996;75:11–16.[Abstract/Free Full Text]

8. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386:73–77.[Medline] [Order article via Infotrieve]

9. Moriwaki H, Kume N, Sawamura T, Aoyama T, Hoshikawa H, Ochi H, Nishi E, Masaki T, Kita T. Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler Thromb Vasc Biol. 1998;18:1541–1547.[Abstract/Free Full Text]

10. Minami M, Kume N, Kataoka H, Morimoto M, Hayashida K, Sawamura T, Masaki T, Kita T. Transforming growth factor-ß(1) increases the expression of lectin-like oxidized low-density lipoprotein receptor-1. Biochem Biophys Res Commun. 2000;272:357–361.[Medline] [Order article via Infotrieve]

11. Aoyama T, Chen M, Fujiwara H, Masaki T, Sawamura T. LOX-1 mediates lysophosphatidylcholine-induced oxidized LDL uptake in smooth muscle cells. FEBS Lett. 2000;467:217–220.[Medline] [Order article via Infotrieve]

12. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, Murase T, Sawamura T, Masaki T, Hashimoto N, Kita T. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation. 1999;99:3110–3117.[Abstract/Free Full Text]

13. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis [see comments]. Science. 1997;275:1132–1136.[Abstract/Free Full Text]

14. Xiang H, Hochman DW, Saya H, Fujiwara T, Schwartzkroin PA, Morrison RS. Evidence for p53-mediated modulation of neuronal viability. J Neurosci. 1996;16:6753–6765.[Abstract/Free Full Text]

15. Isner JM, Kearney M, Bortman S, Passeri J. Apoptosis in human atherosclerosis and restenosis [see comments]. Circulation. 1995;91:2703–2711.[Abstract/Free Full Text]

16. Kockx MM, De Meyer GR, Muhring J, Jacob W, Bult H, Herman AG. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation. 1998;97:2307–2315.[Abstract/Free Full Text]

17. Kume N, Murase T, Moriwaki H, Aoyama T, Sawamura T, Masaki T, Kita T. Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res. 1998;83:322–327.[Abstract/Free Full Text]

18. Kataoka H, Kume N, Miyamoto S, Minami M, Murase T, Sawamura T, Masaki T, Hashimoto N, Kita T. Biosynthesis and post-translational processing of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1): N-linked glycosylation affects cell-surface expression and ligand binding. J Biol Chem. 2000;275:6573–6579.[Abstract/Free Full Text]

19. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986;89:271–277.[Medline] [Order article via Infotrieve]

20. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493–501.[Abstract/Free Full Text]

21. Ortiz EM, Dusetti NJ, Vasseur S, Malka D, Bodeker H, Dagorn JC, Iovanna JL. The pancreatitis-associated protein is induced by free radicals in AR4-2J cells and confers cell resistance to apoptosis. Gastroenterology. 1998;114:808–816.[Medline] [Order article via Infotrieve]

22. Kusuhara M, Chait A, Cader A, Berk BC. Oxidized LDL stimulates mitogen-activated protein kinases in smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 1997;17:141–148.[Abstract/Free Full Text]

23. Jing Q, Xin SM, Cheng ZJ, Zhang WB, Zhang R, Qin YW, Pei G. Activation of p38 mitogen-activated protein kinase by oxidized LDL in vascular smooth muscle cells: mediation via pertussis toxin–sensitive G proteins and association with oxidized LDL-induced cytotoxicity. Circ Res. 1999;84:831–839.[Abstract/Free Full Text]

24. Nishio E, Watanabe Y. Oxysterols induced apoptosis in cultured smooth muscle cells through CPP32 protease activation and bcl-2 protein downregulation. Biochem Biophys Res Commun. 1996;226:928–934.[Medline] [Order article via Infotrieve]

25. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609–619.[Medline] [Order article via Infotrieve]

26. Auge N, Andrieu N, Negre-Salvayre A, Thiers JC, Levade T, Salvayre R. The sphingomyelin-ceramide signaling pathway is involved in oxidized low density lipoprotein-induced cell proliferation. J Biol Chem. 1996;271:19251–19255.[Abstract/Free Full Text]

27. Natarajan V, Scribner WM, Hart CM, Parthasarathy S. Oxidized low density lipoprotein-mediated activation of phospholipase D in smooth muscle cells: a possible role in cell proliferation and atherogenesis. J Lipid Res. 1995;36:2005–2016.[Abstract]

28. Murase T, Kume N, Korenaga R, Ando J, Sawamura T, Masaki T, Kita T. Fluid shear stress transcriptionally induces lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res. 1998;83:328–333.[Abstract/Free Full Text]

29. Moriwaki H, Kume N, Kataoka H, Murase T, Nishi E, Sawamura T, Masaki T, Kita T. Expression of lectin-like oxidized low density lipoprotein receptor-1 in human and murine macrophages: upregulated expression by TNF-. FEBS Lett. 1998;440:29–32.[Medline] [Order article via Infotrieve]

30. Yoshida H, Kondratenko N, Green S, Steinberg D, Quehenberger O. Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem J. 1998;334:9–13.

31. Chen M, Kakutani M, Minami M, Kataoka H, Kume N, Narumiya S, Kita T, Masaki T, Sawamura T. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol. 2000;20:1107–1115.[Abstract/Free Full Text]

32. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation. 2000;101:2889–2895.[Abstract/Free Full Text]

33. Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol. 2000;20:1116–1122.[Abstract/Free Full Text]

34. Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Campagnola M, Rigoni A, Pastorino AM, Lo Cascio V, Sawamura T. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-B through an increased production of intracellular reactive oxygen species. J Biol Chem. 2000;275:12633–12638.[Abstract/Free Full Text]

35. Schonbeck U, Mach F, Sukhova GK, Murphy C, Bonnefoy JY, Fabunmi RP, Libby P. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res. 1997;81:448–454.[Abstract/Free Full Text]

36. Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, Sukhova GK, Libby P. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization [see comments]. Circulation. 1998;97:2433–2444.[Abstract/Free Full Text]

37. Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, Sharifi B, Shah PK. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation. 1999;99:993–998.[Abstract/Free Full Text]

38. Murase T, Kume N, Kataoka H, Minami M, Sawamura T, Masaki T, Kita T. Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arterioscler Thromb Vasc Biol. 2000;20:715–720. [Abstract/Free Full Text]

This article has been cited by other articles:

				D. F. Schaeffer, M. Riazy, K. S. Parhar, J. H. Chen, V. Duronio, T. Sawamura, and U. P. Steinbrecher LOX-1 augments oxLDL uptake by lysoPC-stimulated murine macrophages but is not required for oxLDL clearance from plasma J. Lipid Res., August 1, 2009; 50(8): 1676 - 1684. [Abstract] [Full Text] [PDF]

				S. Ishino, T. Mukai, Y. Kuge, N. Kume, M. Ogawa, N. Takai, J. Kamihashi, M. Shiomi, M. Minami, T. Kita, et al. Targeting of Lectinlike Oxidized Low-Density Lipoprotein Receptor 1 (LOX-1) with 99mTc-Labeled Anti-LOX-1 Antibody: Potential Agent for Imaging of Vulnerable Plaque J. Nucl. Med., October 1, 2008; 49(10): 1677 - 1685. [Abstract] [Full Text] [PDF]

				J. H. Dominguez, J. L. Mehta, D. Li, P. Wu, K. J. Kelly, C. S. Packer, C. Temm, E. Goss, L. Cheng, S. Zhang, et al. Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations Am J Physiol Renal Physiol, January 1, 2008; 294(1): F110 - F119. [Abstract] [Full Text] [PDF]

				N. Duerrschmidt, O. Zabirnyk, M. Nowicki, A. Ricken, F. A. Hmeidan, V. Blumenauer, J. Borlak, and K. Spanel-Borowski Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1-Mediated Autophagy in Human Granulosa Cells as an Alternative of Programmed Cell Death Endocrinology, August 1, 2006; 147(8): 3851 - 3860. [Abstract] [Full Text] [PDF]

				J. L. Mehta, J. Chen, P. L. Hermonat, F. Romeo, and G. Novelli Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): A critical player in the development of atherosclerosis and related disorders Cardiovasc Res, January 1, 2006; 69(1): 36 - 45. [Abstract] [Full Text] [PDF]

				K. Hayashida, N. Kume, T. Murase, M. Minami, D. Nakagawa, T. Inada, M. Tanaka, A. Ueda, G. Kominami, H. Kambara, et al. Serum Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels Are Elevated in Acute Coronary Syndrome: A Novel Marker for Early Diagnosis Circulation, August 9, 2005; 112(6): 812 - 818. [Abstract] [Full Text] [PDF]

				O. Hofnagel, B. Luechtenborg, K. Stolle, S. Lorkowski, H. Eschert, G. Plenz, and H. Robenek Proinflammatory Cytokines Regulate LOX-1 Expression in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1789 - 1795. [Abstract] [Full Text] [PDF]

				K. A. Lindstedt, M. J. Leskinen, and P. T. Kovanen Proteolysis of the Pericellular Matrix: A Novel Element Determining Cell Survival and Death in the Pathogenesis of Plaque Erosion and Rupture Arterioscler Thromb Vasc Biol, August 1, 2004; 24(8): 1350 - 1358. [Abstract] [Full Text] [PDF]

				N. Kume and T. Kita Apoptosis of Vascular Cells by Oxidized LDL: Involvement of Caspases and LOX-1 and Its Implication in Atherosclerotic Plaque Rupture Circ. Res., February 20, 2004; 94(3): 269 - 270. [Full Text] [PDF]

				J. Chen, J. L. Mehta, N. Haider, X. Zhang, J. Narula, and D. Li Role of Caspases in Ox-LDL-Induced Apoptotic Cascade in Human Coronary Artery Endothelial Cells Circ. Res., February 20, 2004; 94(3): 370 - 376. [Abstract] [Full Text] [PDF]

				P. E. Szmitko, C.-H. Wang, R. D. Weisel, G. A. Jeffries, T. J. Anderson, and S. Verma Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation: Part II Circulation, October 28, 2003; 108(17): 2041 - 2048. [Full Text] [PDF]

				P. E. Szmitko, C.-H. Wang, R. D. Weisel, J. R. de Almeida, T. J. Anderson, and S. Verma New Markers of Inflammation and Endothelial Cell Activation: Part I Circulation, October 21, 2003; 108(16): 1917 - 1923. [Full Text] [PDF]

				M. Valgimigli, L. Agnoletti, S. Curello, L. Comini, G. Francolini, F. Mastrorilli, E. Merli, R. Pirani, G. Guardigli, P. G. Grigolato, et al. Serum From Patients With Acute Coronary Syndromes Displays a Proapoptotic Effect on Human Endothelial Cells: A Possible Link to Pan-Coronary Syndromes Circulation, January 21, 2003; 107(2): 264 - 270. [Abstract] [Full Text] [PDF]

				J. L. Mehta and D. Li Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1429 - 1435. [Abstract] [Full Text] [PDF]

				O. Hofnagel, B. Luechtenborg, G. Plenz, H. Robenek, and N. Kume Expression of the Novel Scavenger Receptor SR-PSOX in Cultured Aortic Smooth Muscle Cells and Umbilical Endothelial Cells Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 710 - 711. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Data Supplement Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kataoka, H. Articles by Kita, T. Search for Related Content PubMed PubMed Citation Articles by Kataoka, H. Articles by Kita, T. Pubmed/NCBI databases Substance via MeSH Related Collections Apoptosis Acute coronary syndromes Lipid and lipoprotein metabolism Oxidant stress